The US Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib for unresectable or metastatic non-small cell lung cancer (NSCLC).  It is indicated for adult patients whose tumours have HER2 (ERBB2) mutations and who have received prior systemic therapy.   Under Priority Review, action is expected within six […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!